AHNLAB,INC.
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1995 and listed on KOSDAQ in 2001, AhnLab is an integrated security solutions company. Beyond the V3 antivirus solution, it offers AhnLab TrusGuard, AhnLab XDR, AhnLab EPS, and AhnLab CPP security solutions along with security monitoring services and information security consulting, operating a 24/7 response system through its ASEC (Security Emergency response Center) and CERT (Computer Emergency Response Team). Consolidated revenue for its 31st fiscal year was KRW 267.66 billion, of which product/service revenue (security solutions, monitoring, consulting, etc.) accounted for KRW 251.51 billion (94.0%) and external merchandise accounted for KRW 16.15 billion (6.0%).
Products & technology
- AhnLab V3Antivirus solution
- AhnLab TrusGuardNetwork security appliance
- AhnLab XDRExtended detection and response security solution
- AhnLab EPSProduction-line security solution
- AhnLab CPPSecurity solution
- Security monitoring service24/7 monitoring and response to network security incidents
- Information security consultingSecurity vulnerability assessment and remediation guidance
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIOAI-SearchBot4
Measured since Aug 25, 2026 · 1 AI engines · last read Aug 26, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
KOSDAQ-listed biopharma developing the BVAC cancer immunotherapy vaccine series and the AdCLD-CoV19-1 COVID-19 vaccine.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition